Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
02 Jan 2024
02 Jan 2024
Historique:
received:
15
05
2023
accepted:
14
12
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
epublish
Résumé
No prospective data were available prior to 2021 to inform selection between combination BRAF and MEK inhibition versus dual blockade of programmed cell death protein-1 (PD-1) and cytotoxic T lymphocyte antigen-4 (CTLA-4) as first-line treatment options for BRAFV600-mutant melanoma. SECOMBIT (NCT02631447) was a randomized, three-arm, noncomparative phase II trial in which patients were randomized to one of two sequences with immunotherapy or targeted therapy first, with a third arm in which an 8-week induction course of targeted therapy followed by a planned switch to immunotherapy was the first treatment. BRAF/MEK inhibitors were encorafenib plus binimetinib and checkpoint inhibitors ipilimumab plus nivolumab. Primary outcome of overall survival was previously reported, demonstrating improved survival with immunotherapy administered until progression and followed by BRAF/MEK inhibition. Here we report 4-year survival outcomes, confirming long-term benefit with first-line immunotherapy. We also describe preliminary results of predefined biomarkers analyses that identify a trend toward improved 4-year overall survival and total progression-free survival in patients with loss-of-function mutations affecting JAK or low baseline levels of serum interferon gamma (IFNy). These long-term survival outcomes confirm immunotherapy as the preferred first-line treatment approach for most patients with BRAFV600-mutant metastatic melanoma, and the biomarker analyses are hypothesis-generating for future investigations of predictors of durable benefit with dual checkpoint blockade and targeted therapy.
Identifiants
pubmed: 38167503
doi: 10.1038/s41467-023-44475-6
pii: 10.1038/s41467-023-44475-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
146Informations de copyright
© 2024. The Author(s).
Références
Flaherty, K. T. et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med. 367, 1694–1703 (2012).
pubmed: 23020132
pmcid: 3549295
doi: 10.1056/NEJMoa1210093
Dummer, R. et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 19, 603–615 (2018).
pubmed: 29573941
doi: 10.1016/S1470-2045(18)30142-6
Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23–34 (2015).
pubmed: 26027431
pmcid: 5698905
doi: 10.1056/NEJMoa1504030
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Wang, Y. et al. Anti-PD-1/L1 lead-in before MAPK inhibitor combination maximizes antitumor immunity and efficacy. Cancer Cell. 39, 1375–87.e6 (2021).
pubmed: 34416167
pmcid: 9126729
doi: 10.1016/j.ccell.2021.07.023
Puzanov, I. et al. Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma: pooled analysis of 3 clinical trials. JAMA Oncol. 6, 1256–1264 (2020).
pubmed: 32672795
doi: 10.1001/jamaoncol.2020.2288
Persa, O. D., Fromme, J. E. & Mauch, C. Sequencing of immunotherapy and targeted therapy for BRAF(V600) mutated melanoma: a retrospective study. J. Dtsch Dermatol Ges. 19, 902–904 (2021).
pubmed: 34139097
Frederick, D. T. et al. BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin. Cancer Res. 19, 1225–1231 (2013).
pubmed: 23307859
pmcid: 3752683
doi: 10.1158/1078-0432.CCR-12-1630
Liu, C. et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin. Cancer Res. 19, 393–403 (2013).
pubmed: 23204132
doi: 10.1158/1078-0432.CCR-12-1626
Ho, P.-C. et al. Immune-based antitumor effects of BRAF inhibitors rely on signaling by CD40L and IFNγ. Cancer Res. 74, 3205–3217 (2014).
pubmed: 24736544
pmcid: 4063281
doi: 10.1158/0008-5472.CAN-13-3461
de Andrade, L. F. et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 74, 7298–7308 (2014).
doi: 10.1158/0008-5472.CAN-14-1339
Reddy, S. M., Reuben, A. & Wargo, J. A. Influences of BRAF Inhibitors on the Immune Microenvironment and the Rationale for Combined Molecular and Immune Targeted Therapy. Curr. Oncol. Rep. 18, 42 (2016).
pubmed: 27215436
pmcid: 5330383
doi: 10.1007/s11912-016-0531-z
Ascierto, P. A. et al. Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): a randomized, three-arm, open-label phase II trial. J. Clin. Oncol. 41, 212–221 (2023).
Atkins, M. B. et al. Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial—ECOG-ACRIN EA6134. J. Clin. Oncol. 41, 186–197 (2023).
Fantin, V. R., St-Pierre, J. & Leder, P. Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 9, 425–434 (2006).
pubmed: 16766262
doi: 10.1016/j.ccr.2006.04.023
Brand, A. et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 24, 657–671 (2016).
pubmed: 27641098
doi: 10.1016/j.cmet.2016.08.011
Van Wilpe, S. et al. Lactate dehydrogenase: a marker of diminished antitumor immunity. Oncoimmunology 9, 1731942 (2020).
pubmed: 32158624
pmcid: 7051189
doi: 10.1080/2162402X.2020.1731942
Huber, R. et al. Tumour hypoxia promotes melanoma growth and metastasis via High Mobility Group Box-1 and M2-like macrophages. Sci. Rep. 6, 29914 (2016).
pubmed: 27426915
pmcid: 4947927
doi: 10.1038/srep29914
Zaretsky, J. M. et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. 375, 819–829 (2016).
pubmed: 27433843
pmcid: 5007206
doi: 10.1056/NEJMoa1604958
Shin, D. S. et al. Primary resistance to PD-1 blockade mediated by JAK1/2 mutations. Cancer Discov. 7, 188–201 (2017).
pubmed: 27903500
doi: 10.1158/2159-8290.CD-16-1223
Gkountidi, A. O. et al. MHC Class II antigen presentation by lymphatic endothelial cells in tumors promotes intratumoral regulatory T cell–suppressive functions. Cancer Immunol. Res. 9, 748–764 (2021).
pubmed: 33952631
doi: 10.1158/2326-6066.CIR-20-0784
Dubrot, J. et al. In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer. Nat. Immunol. 23, 1495–1506 (2022).
pubmed: 36151395
doi: 10.1038/s41590-022-01315-x
Maio, M., Altomonte, M., Tatake, R., Zeff, R. A. & Ferrone, S. Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J. Clin. Invest. 88, 282–289 (1991).
pubmed: 1905328
pmcid: 296030
doi: 10.1172/JCI115289
Nirschl, C. J. et al. IFNγ-dependent tissue-immune homeostasis is co-opted in the tumor microenvironment. Cell 170, 127–141.e15 (2017).
pubmed: 28666115
pmcid: 5569303
doi: 10.1016/j.cell.2017.06.016
Pai, C. S. et al. Clonal deletion of tumor-specific T cells by interferon-γ confers therapeutic resistance to combination immune checkpoint blockade. Immunity 50, 477–492.e8 (2019).
pubmed: 30737146
pmcid: 6886475
doi: 10.1016/j.immuni.2019.01.006
Harden, J. L. et al. Dichotomous effects of IFN-γ on dendritic cell function determine the extent of IL-12–driven antitumor T cell immunity. J. Immunol. 187, 126–132 (2011).
pubmed: 21632715
doi: 10.4049/jimmunol.1100168
Diem, S. et al. Serum lactate dehydrogenase as an early marker for outcome in patients treated with anti-PD-1 therapy in metastatic melanoma. Br. J. Cancer 114, 256–261 (2016).
pubmed: 26794281
pmcid: 4742588
doi: 10.1038/bjc.2015.467
Petrelli, F. et al. Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis. Melanoma Res. 29, 1–12 (2019).
pubmed: 30308577
doi: 10.1097/CMR.0000000000000520
Knispel, S. et al. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition. Eur. J. Cancer 148, 61–75 (2021).
pubmed: 33735811
doi: 10.1016/j.ejca.2021.01.034
Hodi, F. S. et al. TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma. Cancer Immunol. Res. 9, 1202–1213 (2021).
pubmed: 34389558
pmcid: 9414280
doi: 10.1158/2326-6066.CIR-20-0983
Ayers, M. et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Investig. 127, 2930–2940 (2017).
pubmed: 28650338
pmcid: 5531419
doi: 10.1172/JCI91190
Grasso, C. S. et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. Cancer Cell. 38, 500–15.e3 (2020).
pubmed: 32916126
pmcid: 7872287
doi: 10.1016/j.ccell.2020.08.005
Giunta, E. F. et al. Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients. Sci. Rep. 10, 17626 (2020).
pubmed: 33077770
pmcid: 7573589
doi: 10.1038/s41598-020-72711-2
Qiu, J. et al. Cancer cells resistant to immune checkpoint blockade acquire interferon-associated epigenetic memory to sustain T cell dysfunction. Nat. Cancer. 4, 43–61 (2023).
Dummer, R. et al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med. 383, 1139–1148 (2020).
Garcia-Diaz, A. et al. Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep. 19, 1189–1201 (2017).
pubmed: 28494868
pmcid: 6420824
doi: 10.1016/j.celrep.2017.04.031
de Vries, N. L. et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743–750 (2023).
pubmed: 36631610
pmcid: 9876799
doi: 10.1038/s41586-022-05593-1
Middha, S. et al. Majority of B2M-mutant and -deficient colorectal carcinomas achieve clinical benefit from immune checkpoint inhibitor therapy and are microsatellite instability-high. JCO Precision Oncol. 3, PO18 (2019).
Zhang, C. et al. B2M and JAK1/2–mutated MSI-H colorectal carcinomas can benefit from anti-PD-1 therapy. J. Immunother. 45, 187–193 (2022).
Torrejon, D. Y. et al. Overcoming genetically based resistance mechanisms to PD-1 blockade. Cancer Discov. 10, 1140–1157 (2020).
pubmed: 32467343
pmcid: 7416458
doi: 10.1158/2159-8290.CD-19-1409
Xie, W. et al. PD-1/PD-L1 pathway: a therapeutic target in CD30+ large cell lymphomas. Biomedicines. 10, 1587 (2022).
Prestipino, A., et al. Oncogenic JAK2(V617F) causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms. Sci. Transl Med. 10, eaam7729 (2018).
Neubert, N. J. et al. Broad and conserved immune regulation by genetically heterogeneous melanoma cells. Cancer Res. 77, 1623–1636 (2017).
pubmed: 28104684
doi: 10.1158/0008-5472.CAN-16-2680
Alspach, E., Lussier, D. M. & Schreiber, R. D. Interferon γ and its important roles in promoting and inhibiting spontaneous and therapeutic cancer immunity. Cold Spring Harb. Perspect. Biol. 11, a028480 (2019).
Zaidi, M. R. & Merlino, G. The two faces of interferon-γ in cancer. Clin. Cancer Res. 17, 6118–6124 (2011).
pubmed: 21705455
pmcid: 3186825
doi: 10.1158/1078-0432.CCR-11-0482
Ribas, A. Adaptive immune resistance: how cancer protects from immune attack. Cancer Discov. 5, 915–919 (2015).
pubmed: 26272491
pmcid: 4560619
doi: 10.1158/2159-8290.CD-15-0563
Spranger, S. et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci. Transl. Med. 5, 200ra116 (2013).
pubmed: 23986400
pmcid: 4136707
doi: 10.1126/scitranslmed.3006504
Wasylecka-Juszczyńska, M. M., Górniak, P., Szydłowski, M., Polak, A. & Juszczyński, P. BRAF V600E mutation in melanoma sustains IFN-gamma inducible PD-L1 expression by coactivating STAT1 and increasing protein translation. Ann. Oncol. 29, viii463–viii464 (2018).
doi: 10.1093/annonc/mdy289.055
Górniak, P. et al. BRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells. Mol. Oncol. 14, 1817–1832 (2020).
pubmed: 32330348
pmcid: 7400781
doi: 10.1002/1878-0261.12695
Gobin, S. J. & van den Elsen, P. J. Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum. Immunol. 61, 1102–1107 (2000).
pubmed: 11137213
doi: 10.1016/S0198-8859(00)00198-1
Cho, H. I., Lee, Y. R. & Celis, E. Interferon γ limits the effectiveness of melanoma peptide vaccines. Blood 117, 135–144 (2011).
pubmed: 20889921
pmcid: 3037740
doi: 10.1182/blood-2010-08-298117
Yu, M. et al. Interferon-γ induces tumor resistance to anti-PD-1 immunotherapy by promoting YAP phase separation. Mol. Cell. 81, 1216–1230.e9 (2021).
pubmed: 33606996
doi: 10.1016/j.molcel.2021.01.010
Jürgens, B., Hainz, U., Fuchs, D., Felzmann, T. & Heitger, A. Interferon-γ–triggered indoleamine 2,3-dioxygenase competence in human monocyte-derived dendritic cells induces regulatory activity in allogeneic T cells. Blood 114, 3235–3243 (2009).
pubmed: 19625705
doi: 10.1182/blood-2008-12-195073
Holmgaard, R. B. et al. Tumor-expressed IDO recruits and activates MDSCs in a Treg-dependent manner. Cell Rep. 13, 412–424 (2015).
pubmed: 26411680
pmcid: 5013825
doi: 10.1016/j.celrep.2015.08.077
Wei, S. C. et al. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies. Proc. Natl Acad. Sci. USA. 116, 22699–22709 (2019).
pubmed: 31636208
pmcid: 6842624
doi: 10.1073/pnas.1821218116
Lund Amanda, W. et al. VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node Lymphatics. Cell Rep. 1, 191–199 (2012).
pubmed: 22832193
doi: 10.1016/j.celrep.2012.01.005
Garnier, L. et al. IFN-ydependent tumor-antigen cross-presentation by lymphatic endothelial cells promotes their killing by T cells and inhibits metastasis. Sci. Adv. 8, eabl5162 (2022).
pubmed: 35675399
pmcid: 9176743
doi: 10.1126/sciadv.abl5162
Parmenter, T. J. et al. Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. Cancer Discov. 4, 423–433 (2014).
pubmed: 24469106
pmcid: 4110245
doi: 10.1158/2159-8290.CD-13-0440
Theodosakis, N. et al. BRAF inhibition decreases cellular glucose uptake in melanoma in association with reduction in cell volume. Mol. Cancer Ther. 14, 1680–1692 (2015).
pubmed: 25948295
pmcid: 4497841
doi: 10.1158/1535-7163.MCT-15-0080
Bottos, A. et al. Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia. Proc. Natl Acad. Sci. USA. 109, E353–E359 (2012).
pubmed: 22203991
doi: 10.1073/pnas.1105026109
Nixon, A. B. et al. Peripheral immune-based biomarkers in cancer immunotherapy: can we realize their predictive potential? J. Immunother. Cancer 7, 325 (2019).
pubmed: 31775882
pmcid: 6880594
doi: 10.1186/s40425-019-0799-2
Eisenhauer, E. A. et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer 45, 228–247 (2009).
pubmed: 19097774
doi: 10.1016/j.ejca.2008.10.026
Szklarczyk, D. et al. The STRING database in 2017: quality-controlled protein-protein association networks, made broadly accessible. Nucleic Acids Res. 45, D362-68 (2017).
Szklarczyk, D. et al. STRING v10: protein-protein interaction networks, integrated over the tree of life. Nucleic Acids Res. 43, D447 (2015).